Long-term results of a hydroxyapatite-coated femoral component in total hip replacement: a 15- to 21-year follow-up study.
Between 1986 and 1991 we implanted 331 consecutive Furlong hydroxyapatite-coated femoral components of a total hip replacement in 291 patients. A cemented acetabular prosthesis was used in 217 hips and a hydroxyapatite-coated component in 114. We describe the long-term clinical and radiological survival of the femoral component at a mean follow-up of 17.5 years (15 to 21). Only two patients (0.68%) were lost to follow-up. With revision of the femoral component for any reason as the endpoint, the survival at a mean of 17 years was 97.4% (95% confidence interval 94.1 to 99.5), and with revision for aseptic loosening as the endpoint it was 100%. The survival at a maximum of 21 years with revision of the femoral component for any reason as the endpoint was 97.4% (95% confidence interval 81.0 or 99.5). These results compare favourably with the best long-term results of cemented or uncemented femoral components used in total hip replacement.
Rajaratnam
S S
SS
Peninsula Orthopaedic Research Institute, 812 Pittwater Road, Deewhy, Sydney, Australia. srajaratnam@talk21.com
Jack
C
C
Tavakkolizadeh
A
A
George
M D
MD
Fletcher
R J
RJ
Hankins
M
M
Shepperd
J A N
JA
D000077:Acetabulum / Q000601:surgery*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019644:Arthroplasty, Replacement, Hip / Q000379:methods*; D001672:Biocompatible Materials / Q000627:therapeutic use*; D002484:Cementation; D017886:Durapatite / Q000627:therapeutic use*; D004739:England; D005500:Follow-Up Studies; D006621:Hip Joint / Q000601:surgery*; D006622:Hip Prosthesis; D006801:Humans; D008875:Middle Aged; D011446:Prospective Studies; D011474:Prosthesis Design; D011475:Prosthesis Failure; D016896:Treatment Outcome
D001672:Biocompatible Materials; D017886:Durapatite